We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
VASH2 promotes oxaliplatin resistance in gastric cancer cells via the AKT signaling pathway.
- Authors
Baoli Lin; Zhi Chen
- Abstract
Gastric cancer (GC) is one of the most common malignant tumors worldwide. GC cells are sensitive to chemotherapy drugs such as oxaliplatin (OHP, trans -/- diaminocyclohexane oxaliplatin or L-OHP). The molecular mechanisms involved in regulation of L-OHP resistance remain unknown. Vasohibin 2 (VASH2), a member of the vasohibin (VASH) family, has been implicated in chemical resistance in several cancer types. However, the possible role of VASH2 in the oxaliplatin resistance of GC is still unclear. In this study, we constructed two L-OHP resistance GC cell lines and found that VASH2 was highly expressed in L-OHP-treated GC cells. Downregulation of VASH2 suppressed the viability of L-OHP-treated GC cells. In addition, VASH2 knockdown stimulated the apoptosis of two oxaliplatin-resistant GC cell lines. In conclusion, our results suggested that VASH2 promoted oxaliplatin resistance in GC cells through the serthreonine protein kinase AKT pathway.
- Subjects
OXALIPLATIN; STOMACH cancer; PROTEIN kinase B; CANCER cells; CELLULAR signal transduction
- Publication
ScienceAsia, 2022, Vol 48, Issue 6, p769
- ISSN
1513-1874
- Publication type
Article
- DOI
10.2306/scienceasia1513-1874.2022.119